Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Loss of Heterozygosity in BRCA1 and BRCA2 Genes in Patients with Ovarian Cancer and Probability of Its Use for Clinical Classification of Variations.

Kechin AA, Boyarskikh UA, Ermolenko NA, Tyulyandina AS, Lazareva DG, Avdalyan AM, Tyulyandin SA, Kushlinskii NE, Filipenko ML.

Bull Exp Biol Med. 2018 May;165(1):94-100. doi: 10.1007/s10517-018-4107-9. Epub 2018 May 24.

PMID:
29797126
2.

[Genetic risk factors for sporadic germ cell testicular tumors].

Nemtsova MV, Ivkin EV, Tryakin AA, Rudenko VV, Dantsev IS, Tyulyandin SA, Loran OB.

Urologiia. 2017 Apr;(1):24-30. Russian.

PMID:
28394519
3.

[ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].

Bogush TA, Popova AS, Dudko EA, Bogush EA, Tyulyandina AS, Tyulyandin SA, Davydov MI.

Antibiot Khimioter. 2015;60(3-4):42-50. Review. Russian.

PMID:
26415382
4.

Analysis of circulating tumor cells in patients with triple negative breast cancer during preoperative chemotherapy.

Lavrov AV, Zubtsova ZhI, Zubtsov DA, Frolova MA, Ignatova EO, Skrypnikova MA, Malysheva EV, Legchenko EV, Petrovskii AV, Utyashev IA, Tyulyandin SA, Gol'dshtein DV.

Bull Exp Biol Med. 2014 May;157(1):159-61. doi: 10.1007/s10517-014-2514-0. Epub 2014 Jun 11.

PMID:
24913582
5.

Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer.

Lyubimova NV, Pashkov MV, Tyulyandin SA, Gol'dberg VE, Kushlinskii NE.

Bull Exp Biol Med. 2004 Jul;138(1):77-9.

PMID:
15514730
6.

Efficacy of combination chemotherapy including Platidiam in the treatment of malignant testicular tumors.

Garin AM, Lichinitser MR, Khlebnov AV, Tyulyandin SA.

Neoplasma. 1987;34(1):85-8.

PMID:
2436066

Supplemental Content

Loading ...
Support Center